Kymera Therapeutics (KYMR) Research & Development (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Research & Development for 8 consecutive years, with $25.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 5.37% year-over-year to $25.0 million; the TTM figure through Mar 2026 stood at $308.1 million (up 145.09% YoY), while the FY2025 annual figure was $316.6 million, up 272.52% from the prior year.
• Research & Development fell to $25.0 million in Q1 2026 per KYMR's latest filing, from $244.9 million in the prior quarter.
• Across five years, Research & Development topped out at $244.9 million in Q4 2025 and bottomed at -$41.4 million in Q4 2023.
• Historically, Research & Development has averaged $43.6 million across 5 years, with a median of $41.3 million in 2022.
• Annual changes were most pronounced in 2023 — Research & Development slumped 196.01% — and 2025, when it surged 820.67%.
• Kymera Therapeutics' Research & Development stood at $43.1 million in 2022, then plunged by 196.01% to -$41.4 million in 2023, then soared by 164.24% to $26.6 million in 2024, then soared by 820.67% to $244.9 million in 2025, then tumbled by 89.81% to $25.0 million in 2026.
• Business Quant data shows KYMR's Research & Development at $25.0 million in Q1 2026, $244.9 million in Q4 2025, and $22.0 million in Q3 2025.